These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 11050076

  • 21. Development of a biologically active secretin analogue incorporating a radioiodinatable photolabile p-(4-hydroxybenzoyl)phenylalanine in position 10.
    Dong M, Pinon DI, Miller LJ.
    Regul Pept; 2002 Nov 15; 109(1-3):181-7. PubMed ID: 12409231
    [Abstract] [Full Text] [Related]

  • 22. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor.
    Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ.
    Mol Pharmacol; 2007 Aug 15; 72(2):280-90. PubMed ID: 17475809
    [Abstract] [Full Text] [Related]

  • 23. Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes.
    Chen Q, Pinon DI, Miller LJ, Dong M.
    J Biol Chem; 2009 Dec 04; 284(49):34135-44. PubMed ID: 19815559
    [Abstract] [Full Text] [Related]

  • 24. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ.
    J Med Chem; 2006 Feb 09; 49(3):850-63. PubMed ID: 16451051
    [Abstract] [Full Text] [Related]

  • 25. Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling.
    Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ.
    Mol Endocrinol; 2006 Jul 09; 20(7):1688-98. PubMed ID: 16513792
    [Abstract] [Full Text] [Related]

  • 26. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
    Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ.
    J Biol Chem; 2005 Jan 14; 280(2):1044-50. PubMed ID: 15520004
    [Abstract] [Full Text] [Related]

  • 27. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG, Miller LJ.
    J Biol Chem; 2005 May 13; 280(19):18631-5. PubMed ID: 15757907
    [Abstract] [Full Text] [Related]

  • 28. A new probe for affinity labelling pancreatic cholecystokinin receptor with minor modification of its structure.
    Fourmy D, Lopez P, Poirot S, Jimenez J, Dufresne M, Moroder L, Powers SP, Vaysse N.
    Eur J Biochem; 1989 Nov 06; 185(2):397-403. PubMed ID: 2583188
    [Abstract] [Full Text] [Related]

  • 29. Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling.
    Coulie B, Matsuura B, Dong M, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ.
    J Biol Chem; 2001 Sep 21; 276(38):35518-22. PubMed ID: 11461914
    [Abstract] [Full Text] [Related]

  • 30. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
    Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller LJ.
    J Biol Chem; 2002 May 24; 277(21):18552-60. PubMed ID: 11893747
    [Abstract] [Full Text] [Related]

  • 31. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands.
    Kopin AS, McBride EW, Quinn SM, Kolakowski LF, Beinborn M.
    J Biol Chem; 1995 Mar 10; 270(10):5019-23. PubMed ID: 7890609
    [Abstract] [Full Text] [Related]

  • 32. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D.
    J Biol Chem; 1997 Jan 31; 272(5):2920-6. PubMed ID: 9006937
    [Abstract] [Full Text] [Related]

  • 33. Use of a nitrotryptophan-containing peptide for photoaffinity labeling the pancreatic cholecystokinin receptor.
    Klueppelberg UG, Gaisano HY, Powers SP, Miller LJ.
    Biochemistry; 1989 Apr 18; 28(8):3463-8. PubMed ID: 2742849
    [Abstract] [Full Text] [Related]

  • 34. Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.
    Chen Q, Pinon DI, Miller LJ, Dong M.
    J Biol Chem; 2010 Aug 06; 285(32):24508-18. PubMed ID: 20529866
    [Abstract] [Full Text] [Related]

  • 35. Molecular basis of agonist binding to the type A cholecystokinin receptor.
    Miller LJ, Lybrand TP.
    Pharmacol Toxicol; 2002 Dec 06; 91(6):282-5. PubMed ID: 12688369
    [Abstract] [Full Text] [Related]

  • 36. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.
    Harikumar KG, Gao F, Pinon DI, Miller LJ.
    Biochemistry; 2008 Sep 09; 47(36):9574-81. PubMed ID: 18700727
    [Abstract] [Full Text] [Related]

  • 37. Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore.
    Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, Abagyan R, Miller LJ.
    J Biol Chem; 2011 Jul 08; 286(27):23888-99. PubMed ID: 21566140
    [Abstract] [Full Text] [Related]

  • 38. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy.
    Pellegrini M, Mierke DF.
    Biochemistry; 1999 Nov 09; 38(45):14775-83. PubMed ID: 10555959
    [Abstract] [Full Text] [Related]

  • 39. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches.
    Miller LJ.
    Yale J Biol Med; 1992 Nov 09; 65(5):441-8; discussion 465-9. PubMed ID: 1340061
    [Abstract] [Full Text] [Related]

  • 40. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus.
    Dong M, Zang M, Pinon DI, Li Z, Lybrand TP, Miller LJ.
    Mol Endocrinol; 2002 Nov 09; 16(11):2490-501. PubMed ID: 12403838
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.